Neuren Pharmaceuticals Ltd (NURPF)
12.60
0.00 (0.00%)
USD |
OTCM |
Jun 14, 16:00
Neuren Pharmaceuticals Enterprise Value: 1.482B for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 14, 2024 | 1.482B |
| June 13, 2024 | 1.482B |
| June 12, 2024 | 1.482B |
| June 11, 2024 | 1.482B |
| June 10, 2024 | 1.547B |
| June 07, 2024 | 1.664B |
| June 06, 2024 | 1.664B |
| June 05, 2024 | 1.664B |
| June 04, 2024 | 1.664B |
| June 03, 2024 | 1.664B |
| May 31, 2024 | 1.664B |
| May 30, 2024 | 1.599B |
| May 29, 2024 | 1.599B |
| May 28, 2024 | 1.599B |
| May 24, 2024 | 1.652B |
| May 23, 2024 | 1.652B |
| May 22, 2024 | 1.652B |
| May 21, 2024 | 1.606B |
| May 20, 2024 | 1.606B |
| May 17, 2024 | 1.606B |
| May 16, 2024 | 1.606B |
| May 15, 2024 | 1.606B |
| May 14, 2024 | 1.493B |
| May 13, 2024 | 1.493B |
| May 10, 2024 | 1.470B |
| Date | Value |
|---|---|
| May 09, 2024 | 1.470B |
| May 08, 2024 | 1.466B |
| May 07, 2024 | 1.466B |
| May 06, 2024 | 1.466B |
| May 03, 2024 | 1.466B |
| May 02, 2024 | 1.466B |
| May 01, 2024 | 1.466B |
| April 30, 2024 | 1.466B |
| April 29, 2024 | 1.466B |
| April 26, 2024 | 1.466B |
| April 25, 2024 | 1.466B |
| April 24, 2024 | 1.469B |
| April 23, 2024 | 1.469B |
| April 22, 2024 | 1.469B |
| April 19, 2024 | 1.469B |
| April 18, 2024 | 1.469B |
| April 17, 2024 | 1.469B |
| April 16, 2024 | 1.469B |
| April 15, 2024 | 1.469B |
| April 12, 2024 | 1.577B |
| April 11, 2024 | 1.577B |
| April 10, 2024 | 1.621B |
| April 09, 2024 | 1.621B |
| April 08, 2024 | 1.621B |
| April 05, 2024 | 1.626B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
46.78M
Minimum
Mar 24 2020
2.157B
Maximum
Dec 28 2023
510.98M
Average
288.13M
Median
Jul 05 2022
Enterprise Value Benchmarks
| Alterity Therapeutics Ltd | -- |
| Kazia Therapeutics Ltd | 3.883M |
| Immutep Ltd | -- |
| Opthea Ltd | 4.905M |
| Mesoblast Ltd | -- |
Enterprise Value Related Metrics
| Earnings Yield | 6.26% |
| Operating Earnings Yield | 7.92% |
| Normalized Earnings Yield | 6.257 |